Vivoryon Therapeutics N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
17 nov 2014 - 08:48
Statutaire naam
Vivoryon Therapeutics N.V.
Titel
Probiodrug to present data on therapeutic concept of targeting pyro-Glu Abeta and its frontrunner QC-inhibitor PQ912 at International Alzheimer Conferences
Bericht
Probiodrug to present data on therapeutic concept of targeting pyro-Glu Abeta and its frontrunner QC-inhibitor PQ912 at International Alzheimer Conferences
Presentation at Society for Neuroscience (SfN) and Poster at Clinical Trials on Alzheimer's Disease (CtaD)
HALLE/SAALE, Germany, 17 November 2014 - Probiodrug AG ("Probiodrug"), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's Disease, announces that Prof. Hans-Ulrich Demuth, co- founder and consultant of Probiodrug, will be reviewing the target validation and summarize data on its lead product candidate PQ912 at two international conferences.
The presentation and poster en
Gerelateerde downloads
Datum laatste update: 20 december 2025